Trending News: Median Incubation Period for Novel Coronavirus is Approximately Five Days
Top news from across the health care landscape.
In patients with chronic obstructive pulmonary disease (COPD), platelet indices may be altered and, therefore, act as a valuable diagnostic market in COPD development, according to The American Journal of Managed Care. New research aimed to determine the differences in platelet-related parameters between controls and participants with COPD. The study authors hypothesized that platelet indices are disturbed in patients with COPD while C-reactive protein, fibrinogen, and white blood cells are increased. The researchers concluded that while platelet indices have demonstrated the ability to be a valuable diagnostic marker, whereas reproducibility in clinical practice must be assessed in the future.
Although low-dose aspirin has long been a staple in treatment for patients at risk of cardiovascular disease, new findings from an international team of researchers suggests a potential link between the use of aspirin and a reduction in the most common type of liver cancer, according to HCP Live. The study authors analyzed data from more than 50,000 patients and found that those at high risk of developing hepatocellular carcinoma who were receiving low-dose aspirin saw reductions in cancer and liver-related deaths. An additional observed benefit was also greater the longer an individual was taking low-dose aspirin.
The median incubation period for the novel coronavirus (COVID-19) is approximately 5 days, similar to SARS, according to Contagion Live. Researchers from John Hopkins Bloomberg School of Public Health analyzed published information about COVID-19 in order to estimate the length of the incubation period from exposure to symptom onset. Of 181 confirmed, observed cases of COVID-19, researchers found that the median incubation period of the disease was about 5.1 days and that approximately 97.5% of those who develop symptoms did so within 11.5 days of infection.